Quantcast

Latest University of Texas Health Science Center at San Antonio Stories

2009-02-04 11:15:00

CALGARY, Feb. 4 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) and the Cancer Therapy & Research Center at The University of Texas Health Science Center in San Antonio, (CTRC at UTHSCSA) announced a broad preclinical and clinical collaboration involving up to five, open-label, Phase 2 studies exploring the use of REOLYSIN(R) in combination with chemotherapy for various cancer indications. These indications are expected to include melanoma,...

2008-10-06 15:00:41

LOS ANGELES, Oct. 6, 2008 (GLOBE NEWSWIRE) -- Charles Drew University of Medicine and Science (CDU) has been awarded a major $15 million endowment grant that will significantly expand its medical research infrastructure and capacity from the National Institutes of Health, through its National Center for Minority Health and Health Disparities (NCMHD), it was announced today by Dr. Susan Kelly, President and CEO of CDU. With the new grant, the university's research endowment base will grow to...

2008-09-29 21:00:31

By Daniel Connolly The Regional Medical Center at Memphis plans to ask the University of Tennessee Health Science Center about participating in its plan to build a new clinical office on Union that would attract paying patients. The Med's interest in the project reflects its desire to earn money and turn around a projected $14.4 million operating loss this fiscal year. Hospital board chairman Gene Holcomb said Thursday that he wants The Med's new interim CEO, Claude Watts Jr., to...

2008-09-16 12:00:50

Three internationally known pediatric surgeons from The University of Texas Health Science Center at San Antonio and its academic children's hospital, CHRISTUS Santa Rosa Children's Hospital, are this year's recipients of the prestigious Julio Palmaz Award for Innovation in Healthcare and the Biosciences. Robert M. Campbell, Jr., M.D., Melvin D. Smith, M.D. (deceased) and Kaye E. Wilkins, D.V.M., M.D. are each being honored for devising innovative ideas that have had tangible, life-saving...

2008-09-15 12:00:35

SCOTTSDALE, Ariz., Sept. 15 /PRNewswire/ -- Carefx Corporation today announced that the nationally recognized Cancer Therapy & Research Center (CTRC) at the University of Texas Health Science Center at San Antonio, Texas, has gone live after a 90-day implementation with Fusion from Carefx(R), an interoperability platform that aligns patient data across multiple applications to provide a complete view of patient health history. One of only three National Cancer Institute-designated...

2008-09-05 06:00:23

US-based pharmaceutical company Azaya Therapeutics has signed a licensing agreement to further develop a technology that uses liposomes to deliver radiation through direct injection into head and neck tumors, shrinking the tumor, delaying recurrence and avoiding the collateral tissue damage that often accompanies all other forms of radiation therapy. The company plans to begin a Phase I clinical trial in early 2010. Azaya is licensing the technology, now known as Azaya Liposomal...

2008-09-03 12:00:33

Azaya Therapeutics, Inc., announced today that it has signed a licensing agreement to further develop a breakthrough technology that uses liposomes to deliver radiation through direct injection into head and neck tumors, shrinking the tumor, delaying recurrence and avoiding the collateral tissue damage that often accompanies all other forms of radiation therapy. The company plans to begin a phase I clinical trial in early 2010. Azaya is licensing the technology, now known as Azaya...

2008-06-20 03:00:29

CALGARY, June 20 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that following U.S. Food and Drug Administration (FDA) review, the Company is initiating a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers. The Principal Investigator is Dr. Monica Mita of the Cancer Therapy and Research Center, University of Texas...

2007-08-09 12:04:00

Michael J. Wick, Ph.D., a recognized leader in the research of new anti-cancer drugs, has been named director of preclinical research at South Texas Accelerated Research Therapeutics (START). He will join the START team on Sept. 3. Dr. Wick comes to START from the Cancer Therapy & Research Center's (CTRC) Institute for Drug Development, where he was director of preclinical research. He is a recognized expert in the testing of novel therapies in animal models of human cancer....

2007-08-08 12:09:12

Chris H. M. Takimoto, M.D., Ph.D., an internationally recognized leader in the development of new anti-cancer drugs, has been named director of pharmacology at South Texas Accelerated Research Therapeutics (START). Dr. Takimoto comes to START from the Cancer Therapy & Research Center's Institute for Drug Development, where he was pharmacology director and held the Zachry Chair of Translational Research. START, a clinical research organization focused on developing new anti-cancer...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related